Novartis AG v. Union of India & Others

Court: Supreme Court of India | Date of Decision: 1 April 2013 Case Numbers: Civil Appeal Nos. 2706–2716 of 2013 (arising out of SLP(C) Nos. 20539–20549 of 2009); Civil Appeal No. 2728 of 2013 (arising out of SLP(C) No. 32706 of 2009); Civil Appeal Nos. 2717–2727 of 2013 (arising out of SLP(C) Nos. 12984–12994 of 2013) Bench: Justice Aftab Alam and Justice Ranjana Prakash Desai Citation: AIR 2013 SC 1311; 2013 AIR SCW 2047; (2013) 6 SCC 1; (2013) 5 SCALE 12; (2013) 3 Mad LJ 421; (2013) 3 Mad LW 449; (2013) 4 All WC 3611; (2013) 115 CORLA 7.2 SN; (2013) 3 KCCR 276 SN; (2013) 2 RecCivR 685 Author of the Judgment: Justice Aftab Alam

BACKGROUND

The appellant in the principal appeals, Novartis AG, is a multinational pharmaceutical company. The respondents include the Union of India, the Intellectual Property Appellate Board, the Assistant Controller of Patents and Designs and several generic pharmaceutical companies and patient organisations, namely NATCO Pharma Ltd., Cipla Ltd., Ranbaxy Laboratories Ltd., Hetero Drugs Ltd. and M/s Cancer Patients Aid Association, who had filed pre-grant oppositions and were also appellants in cross-appeals before the Supreme Court.

The subject matter of the dispute is the claim by Novartis AG for grant of patent for the beta crystalline form of a chemical compound called Imatinib Mesylate, which is a therapeutic drug for chronic myeloid leukemia and certain kinds of tumours, marketed under the trade names “Glivec” or “Gleevec.” The case raises fundamental questions concerning the true import of Section 3(d) of the Patents Act, 1970, its interplay with clauses (j) and (ja) of Section 2(1) and the tests to be applied in determining whether a product qualifies as an “invention” entitled to patent protection in India.

The provenance of the subject product must be understood in stages. Jürg Zimmermann invented a number of derivatives of N-phenyl-2-pyrimidine-amine, one of which is the compound eventually given the International Nonproprietary Name “Imatinib” by the World Health Organisation. These derivatives were found capable of inhibiting certain protein kinases and thus have valuable anti-tumour properties. The Zimmermann derivatives, including Imatinib, were granted a United States patent on 28 May 1996 under US Patent No. 5,521,184 and a European patent under Patent No. EP-A-0 564 409. The Zimmermann patent expressly described the compounds of formula I, including their pharmaceutically acceptable salts and the claims included, under serial number 23, the specific compound Imatinib, described as compound of formula I or a pharmaceutically acceptable salt thereof.

The appellant claimed that, starting from Imatinib in free base form as the “e-duct,” it arrived at Imatinib Mesylate (the methanesulfonic acid addition salt of Imatinib) through a first inventive stage and then at the beta crystalline form of Imatinib Mesylate through a second inventive stage. The appellant filed application No. 1602/MAS/1998 at the Chennai Patent Office on 17 July 1998, for grant of patent for Imatinib Mesylate in beta crystalline form. The application was given priority from 18 July 1997, being the date on which the appellant had applied for patent in Switzerland. In the patent application, the appellant claimed that the beta crystal form of Imatinib Mesylate possesses more beneficial flow properties, better thermodynamic stability and lower hygroscopicity than the alpha crystal form. It further claimed that the free base Imatinib equally possesses all the indicated inhibitory and pharmacological effects of the beta crystalline form.

The application was filed at a time when the Patents Act, 1970, still contained Section 5, which barred product patents for pharmaceutical substances and accordingly lay dormant under the “mailbox” procedure. The appellant also filed an application for Exclusive Marketing Rights (EMR) under the then-operative Section 24A of the Act; EMR was granted on 10 November 2003. Following EMR, Gleevec was marketed in India at a price of approximately Rs. 1,20,000 per month for a required dose, while generic versions were available at Rs. 8,000 to Rs. 10,000.

Before the patent application was taken up for consideration, fundamental amendments were made to the Patents Act, 1970, in three legislative stages the Patents (Amendment) Acts of 1999, 2002 and 2005 primarily to bring India’s patent law into compliance with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The most consequential amendment for the present case was effected by the Patents (Amendment) Act, 2005, which deleted Section 5 of the parent Act (thereby opening the doors to pharmaceutical product patents) and simultaneously amended Section 3(d) by adding new words at the commencement of the clause and inserting an Explanation thereto.

After the mailbox application was taken out for consideration, five pre-grant oppositions were filed under Section 25(1) of the Act by, respectively, M/s Cancer Patients Aid Association, NATCO Pharma Ltd., Cipla Ltd., Ranbaxy Laboratories Ltd. and Hetero Drugs Ltd. The appellant filed four expert affidavits in response, two of which asserted that the beta crystal form of Imatinib Mesylate had approximately thirty percent higher bioavailability as compared to Imatinib in free base form.

The Assistant Controller of Patents and Designs heard all parties on 15 December 2005 and rejected the patent application by five separate orders passed on 25 January 2006, holding that the invention was anticipated by the Zimmermann patent, that it was obvious to a person skilled in the art in view of that patent and that its patentability was barred by Section 3(d) of the Act. The appellant challenged these orders in writ petitions before the Madras High Court. The appellant also filed writ petitions challenging the constitutional validity of Section 3(d) on the grounds that it violated Article 14 of the Constitution and was not TRIPS-compliant; these were dismissed by a Division Bench of the Madras High Court on 6 August 2007 and the appellant did not pursue the matter further. The five writ petitions challenging the Assistant Controller’s orders were transferred to the Intellectual Property Appellate Board (IPAB) on 4 April 2007 and were registered as appeals numbered TA/1 to 5/2007/PT/CH.

The IPAB, by a detailed judgment dated 26 June 2009, reversed the Assistant Controller’s findings on anticipation and obviousness, holding that the invention satisfied the tests of novelty and non-obviousness and also held that the appellant was entitled to claim 18 July 1997 as its priority date. However, the IPAB upheld the bar under Section 3(d) and dismissed the product patent claims. The IPAB additionally observed, with reference to Section 3(b), that the grant of product patent on this application could have disastrous consequences for cancer patients in India given the high price charged for Gleevec during the EMR period. The IPAB, however, held that the appellant could not be denied a process patent for the preparation of Imatinib Mesylate in beta crystalline form and ordered accordingly.

Novartis AG challenged the IPAB’s order directly before the Supreme Court by way of petitions under Article 136 of the Constitution. NATCO Pharma Ltd. and M/s Cancer Patients Aid Association also filed separate Special Leave Petitions challenging the IPAB’s findings in favour of Novartis on novelty and non-obviousness. Leave was granted in all the SLPs and the Supreme Court took up the appeals for final decision, noting that by reason of the history of earlier hearings and the impending expiry of the twenty-year patent term in July 2018, relegating the matter to the High Court would render the proceedings infructuous. The Court, however, expressly clarified that this procedure was not to be treated as a precedent authorising direct challenges to IPAB orders before the Supreme Court bypassing the High Court.

The Court further noted the significant legislative history of India’s patent law tracing the development from the Patents and Designs Act of 1911, through the recommendations of the Bakshi Tek Chand Committee (1949–1950) and the Justice Rajagopala Ayyangar Committee (1957–1959), to the enactment of the Patents Act, 1970 and considered in some detail the transformation of the Indian pharmaceutical industry in the decades following the 1970 Act, in which market shares shifted decisively in favour of Indian manufacturers as a result of the process-only patent regime for pharmaceutical substances. The Court also examined the TRIPS Agreement, including its Articles 1, 7, 8 and 27 and the Doha Declaration on TRIPS and Public Health of 14 November 2001, in order to understand the legislative context of the 2005 amendments.

ISSUES FOR DETERMINATION

1. The Court was required to determine whether, as a threshold matter, the subject product the beta crystalline form of Imatinib Mesylate qualifies as a “new product” within the meaning of Section 2(1)(j) of the Patents Act, 1970, read with Section 2(1)(ja), that is, whether it comes into being through an invention having a feature that involves technical advance over existing knowledge or having economic significance and that makes the invention not obvious to a person skilled in the art.
2. The Court was required to determine whether Imatinib Mesylate (the non-crystalline form) is a known substance from the Zimmermann patent or whether it constitutes a new product brought into existence through an independent invention and what consequences flow from the answer to that question for the appellant’s claim.
3. The Court was required to determine the true import of Section 3(d) of the Patents Act, 1970, as amended with effect from 1 January 2005 specifically, whether it operates as an independent second tier of patentability standards or merely as a provision ex majore cautela supplementing the definition of “invention” in clauses (j) and (ja) of Section 2(1) and whether it has any application to the subject product.
4. The Court was required to determine what constitutes “enhanced efficacy” of a known substance within the meaning of Section 3(d) and the Explanation appended thereto and specifically whether the physico-chemical properties claimed for the beta crystalline form of Imatinib Mesylate namely, more beneficial flow properties, better thermodynamic stability, lower hygroscopicity and approximately thirty percent higher bioavailability over Imatinib in free base form satisfy the test of enhanced efficacy as required by Section 3(d).
5. As a contextual issue, the Court was called upon to consider whether the dichotomy sought to be drawn by the appellant between “coverage” or “claim” in a patent and “disclosure” or “enabling teaching” in that patent is sound in principle and whether such a distinction could affect the finding as to whether Imatinib Mesylate is a known substance from the Zimmermann patent.

KEY HOLDINGS OF THE COURT

• On the status of Imatinib Mesylate under the Zimmermann patent, the Court held that Imatinib Mesylate is a known substance from the Zimmermann patent itself. The Court based this finding on an objective consideration of all the material facts and circumstances: the express terms of the Zimmermann patent describing compounds of formula I together with their pharmaceutically acceptable salts; the appellant’s own representations to the US FDA in connection with the New Drug Application for Gleevec, in which it declared that the drug Gleevec (Imatinib Mesylate) was covered by the Zimmermann patent; the Patent Term Extension Application filed by the appellant stating that Imatinib or any salt thereof including Imatinib Mesylate, had not previously been approved for commercial marketing; and the legal notice issued by the appellant to NATCO Pharma Ltd. in the UK asserting that VEENAT 100 capsules (active ingredient: Imatinib Mesylate) infringed the Zimmermann patent. The Court further found that not only is Imatinib Mesylate a known substance from the Zimmermann patent, but its pharmacological properties are also known from the Zimmermann patent and from the article published in the Cancer Research journal of January 1996. The Court accordingly held that Imatinib Mesylate does not qualify the test of “invention” as laid down in Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970.
• on the submission that a distinction must be drawn between “coverage” and “disclosure” in a patent, the Court firmly rejected this argument. The Court observed that to say the coverage in a patent might go much beyond the disclosure negates the fundamental rationale of the patent system, under which a monopoly is granted in exchange for the invention being made public. The Court declined to apply the US Court of Customs and Patent Appeals decision in In re Hogan (559 F.2d 595), noting that it was a decision rendered on extraordinary facts in a very different context, that later Federal Circuit decisions in Plant Genetics System, N.V. v. DeKalb Genetics Corp. and Chiron Corp. v. Genentech, Inc. had drastically narrowed its precedential scope and that the finding that Imatinib Mesylate was a known substance rendered Hogan inapplicable in any event. The Court expressed that it did not wish the law of patent in India to develop on lines where there would be a vast gap between coverage and disclosure, where the scope of patent was determined by the artful drafting of claims rather than the intrinsic worth of the invention and where patents were traded as a commodity rather than serving the objects of production and marketing of patented products.
• on the nature and scope of Section 3(d), the Court rejected the submission that Section 3(d) is a provision ex majore cautela or ex abundanti cautela supplementing Sections 2(1)(j) and 2(1)(ja) without independent operative force. The Court held that this submission completely misses the vital distinction between the concepts of “invention” and “patentability” a distinction that was at the heart of the Patents Act as framed in 1970 and which is reinforced by the 2005 amendment in Section 3(d). The Court observed that the amendment to Section 3(d) was the specific provision cited by the Government during the Parliamentary debates to allay Opposition fears about the abuse of product patents in pharmaceutical substances and that the amended provision clearly sets up a second tier of qualifying standards for chemical substances and pharmaceutical products in order to leave the door open for true and genuine inventions while checking repetitive patenting or extension of the patent term on spurious grounds.
• on the meaning of “efficacy” in Section 3(d) and whether the subject product satisfies the test of enhanced efficacy, the Court held that in the context of a medicine, the test of efficacy can only be “therapeutic efficacy.” The Court further held that “therapeutic efficacy” must be judged strictly and narrowly, given the legislative history and the specific context in which the amendment to Section 3(d) was made. The Court held that not all advantageous or beneficial properties are relevant for the purpose of Section 3(d) only properties that directly relate to therapeutic efficacy. The physico-chemical properties of the beta crystalline form of Imatinib Mesylate namely, more beneficial flow properties, better thermodynamic stability and lower hygroscopicity may be otherwise beneficial but have nothing to do with therapeutic efficacy and cannot be taken into account for the purpose of Section 3(d). On the question of increased bioavailability, the Court declined to definitively rule on whether bioavailability falls within or outside the concept of “efficacy” as contended by counsel for one of the Objectors, but held that a bare assertion of approximately thirty percent increased bioavailability of the beta crystalline form over Imatinib in free base form does not by itself establish enhancement of therapeutic efficacy. Whether increased bioavailability leads to enhanced therapeutic efficacy in a given case must be specifically claimed and established by research data; no such material was before the Court. Furthermore, the Court noted that the appellant’s own patent application stated unambiguously that all the indicated inhibitory and pharmacological effects of the beta crystalline form of Imatinib Mesylate are also found with the Imatinib free base, which was a clear admission negating any claim of enhanced therapeutic efficacy over the preceding known substance. The Court also noted the fundamental weakness in the appellant’s case that there was no material comparing the efficacy or even the solubility of the beta crystalline form of Imatinib Mesylate with Imatinib Mesylate in non-crystalline form, which the Court had found to be the known substance immediately preceding the subject product.
• on the final operative order: the Court held that the beta crystalline form of Imatinib Mesylate fails both the test of “invention” under Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970 and the test of “patentability” under Section 3(d) thereof. The appeals filed by Novartis AG were accordingly dismissed with costs. The cross-appeals filed by NATCO Pharma Ltd. and M/s Cancer Patients Aid Association were allowed.

The Court expressly clarified that this judgment does not hold that Section 3(d) bars patent protection for all incremental inventions of chemical and pharmaceutical substances and that it would be a grave mistake to read the judgment as meaning that Section 3(d) was amended with the intent to undo the fundamental change brought about in the patent regime by the deletion of Section 5 from the parent Act.

STATUTORY PROVISIONS INVOLVED

Section 2(1)(j) of the Patents Act, 1970, as amended by the Patents (Amendment) Act, 2002, defines “invention” to mean a new product or process involving an inventive step and capable of industrial application. The Court applied this definition to hold that Imatinib Mesylate, being a known substance from the Zimmermann patent, does not qualify as a “new product” and therefore fails the threshold test of “invention” under this clause. The Court explained that the definition, read in conjunction with clause (ja), requires a product to be new, to be capable of being made or used in an industry and to come into being as a result of an invention having a feature that entails technical advance over existing knowledge or has economic significance and that makes the invention not obvious to a person skilled in the art.

Section 2(1)(ja) of the Patents Act, 1970, inserted by the Patents (Amendment) Act, 2002 and further amended by the 2005 Act, defines “inventive step” to mean a feature of an invention that involves technical advance as compared to the existing knowledge or having economic significance or both and that makes the invention not obvious to a person skilled in the art. The Court applied this provision in determining whether the appellant’s claimed inventions constituted genuine inventive steps beyond the Zimmermann patent.

Section 3(d) of the Patents Act, 1970, as amended by the Patents (Amendment) Act, 2005, was the central provision under consideration. As amended, it provides that the following are not inventions within the meaning of the Act: the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant. The Explanation to the provision specifies that salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of a known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy. The Court interpreted this provision as establishing a second and independent tier of qualifying standards for chemical substances and pharmaceutical products, distinct from the tests of “invention” in Sections 2(1)(j) and 2(1)(ja). The Court applied Section 3(d) and its Explanation to hold that the beta crystalline form of Imatinib Mesylate, being a polymorph of Imatinib Mesylate and thus a new form of a known substance, must demonstrate enhancement of known efficacy specifically, therapeutic efficacy in order to escape the bar of the provision. The Court held that the appellant failed to demonstrate such enhancement.

Section 10(4) and (5) of the Patents Act, 1970 were referred to in the context of the Court’s rejection of the submission that coverage in a patent may extend well beyond its disclosure. Section 10(4) requires every complete specification to fully and particularly describe the invention and the method of performing it, to disclose the best method of performing the invention and to end with claims defining the scope of the invention. Section 10(5) requires that claims relate to a single invention or to a group of inventions forming a single inventive concept, be clear and succinct and be fairly based on the matter disclosed in the specification. The Court relied on these provisions to reinforce the proposition that the scope of a claim and its enabling disclosure cannot be fundamentally divergent.

Section 13(4) of the Patents Act, 1970 was referred to in the contextual discussion to note that the grant of a patent does not guarantee its validity, this position having been expressly enacted in the statute.

Section 83 of the Patents Act, 1970, as introduced by the 2002 amendment, was reproduced in the judgment as part of the legislative history discussion. It lays down the general principles applicable to working of patented inventions, including that patents should be granted to encourage inventions and to make the benefit of patented inventions available at reasonably affordable prices to the public.

Section 64(1)(e) and (f) of the Patents Act, 1970 were referred to in the context of the interpretation of the expression “publicly known” in the context of revocation of patents, as a comparator for interpreting the word “known” in Section 3(d). The Court applied the principle from Monsanto Company v. Coramandal Indag Products (P) Ltd. that “publicly known” does not require wide consumer knowledge but is sufficient if the substance is known to persons engaged in the pursuit of knowledge of the patented product or process as men of science or commerce.

Articles 1, 7, 8, 27, 63, 64, 65 and 70 of the TRIPS Agreement were set out and discussed as the international treaty framework underlying the 2005 amendments to the Patents Act. The Court considered these provisions to understand the “why” and “how” of the law, without making any pronouncements on the fairness or otherwise of the Agreement or India’s decision to subscribe to it. The Doha Declaration on TRIPS and Public Health of 14 November 2001 was also referred to as contextual material reflecting the concerns of developing countries regarding patent protection for pharmaceutical substances.

REASONING OF THE COURT

The Court’s reasoning is structured around the legislative history of Indian patent law, the meaning of the key statutory definitions and the application of those definitions and the bar under Section 3(d) to the specific facts of the case.

The Court began by emphasising that to correctly understand the present law it is essential to know the “why” and “how” of the law, invoking the principles of purposive statutory interpretation affirmed by the Supreme Court in Utkal Contractors and Joinery Pvt. Ltd. v. State of Orissa and Reserve Bank of India v. Peerless General Finance and Investment Co. Ltd. Against this backdrop, the Court traced the history of patent law in India from the Patents and Designs Act, 1911, through the recommendations of the Ayyangar Committee, to the enactment of the Patents Act, 1970. This history established that the Indian legislature had deliberately chosen, in the 1970 Act, to exclude product patents for pharmaceutical and chemical substances in order to enable the indigenous pharmaceutical industry to develop and to keep medicines affordable. The Court then traced the progressive transformation of the Indian pharmaceutical industry in the decades following the 1970 Act, documenting the rise of Indian companies from a market share of thirty-two percent in 1970 to seventy-seven percent by 2004 and the emergence of India as a major global supplier of affordable generic medicines.

The Court next examined the TRIPS Agreement and the legislative history of the 2005 amendments. It observed that Parliament was confronted with the unenviable task of forging legislation that would be TRIPS-compliant while protecting the public health objectives that had driven the 1970 Act. The Court paid particular attention to the Parliamentary debates preceding the passage of the Patents (Amendment) Act, 2005, noting that the amendment to Section 3(d) was repeatedly cited by the Government as the specific safeguard against “evergreening” the practice of obtaining successive patents for minor modifications of known substances in order to extend the period of monopoly and that the Bill was passed largely on the strength of the Government’s assurance that the amended Section 3(d) would prevent such abuse.

On the first tier of analysis whether the subject product qualifies as an “invention” the Court considered the relationship between the Zimmermann patent and Imatinib Mesylate in detail. The Court noted the express language of the Zimmermann patent describing compounds of formula I together with their salts, the publications in Cancer Research and Nature Medicine authored by Zimmermann himself which discussed Imatinib Mesylate and its in vivo anti-tumour activity and the appellant’s own conduct in representing to the US FDA, in the Patent Term Extension Application and in the legal notice to NATCO Pharma Ltd. that Gleevec (Imatinib Mesylate) was covered by and derived from the Zimmermann patent. The Court rejected the submission that conduct of the patentee subsequent to the grant of a patent is irrelevant to construing it, observing that the finding as to the known character of Imatinib Mesylate was not based solely on the appellant’s conduct but on an objective assessment of all the materials. The Court further rejected the submission based on the dichotomy between “coverage” and “disclosure,” holding that such an approach would negate the fundamental rationale of the patent system and would be contrary to the express requirements of Section 10(4) and (5) of the Patents Act, as well as analogous provisions of the UK Patents Act, 1977 and the US Code. On this basis, the Court firmly concluded that Imatinib Mesylate was a known substance from the Zimmermann patent and failed the test of “invention” under Sections 2(1)(j) and 2(1)(ja).

On the second tier of analysis Section 3(d) the Court held that even assuming, for the sake of argument, that the beta crystalline form of Imatinib Mesylate was new in the sense of not being known from the Zimmermann patent, it directly attracted Section 3(d) as a polymorph of Imatinib Mesylate, a known substance of known efficacy. The Court interpreted the word “known” in Section 3(d) against the submission that it meant “proven beyond doubt,” holding that there is no sanction for that construction and relying on the Supreme Court’s interpretation in Monsanto v. Coramandal Indag Products that it suffices if the substance is known to persons engaged in the pursuit of knowledge of the patented product or process as men of science or commerce.

The Court then interpreted the key phrase “enhancement of the known efficacy” in Section 3(d). Drawing on the constitutional purpose of patent law and the specific legislative history of the 2005 amendment, the Court held that in the case of a medicine the test of efficacy is necessarily therapeutic efficacy and that this test must be applied strictly and narrowly. The Court observed that the Explanation to Section 3(d) makes clear that forms such as polymorphs, unless differing significantly in properties with regard to efficacy, are to be treated as the same substance as the known substance; and that each form carries certain properties inherent to it such as solubility to a salt and hygroscopicity to a polymorph which would not qualify as enhancement of efficacy. The Court found that the physico-chemical properties asserted for the beta crystalline form (flow properties, thermodynamic stability, hygroscopicity) have no bearing on therapeutic efficacy and must be set aside entirely. On bioavailability, the Court declined to categorically rule on whether it is a pharmacokinetic or pharmacodynamic property, but held that a bald assertion of thirty percent increased bioavailability, without specific research data establishing that such increase translates into enhanced therapeutic efficacy on a molecular basis in vivo, is wholly insufficient. The Court further found that the appellant’s patent application itself stated that all the pharmacological properties of the beta crystalline form are equally found with the Imatinib free base a statement that entirely undermines any claim of enhanced efficacy over the known substance. The Court also pointed out the fundamental inconsistency in the appellant’s case: throughout the patent application and affidavits, the comparison was made between the beta crystalline form and Imatinib in free base, whereas the Court had found the substance immediately preceding the subject product to be Imatinib Mesylate (non-crystalline) and no comparison whatsoever was made between the beta crystalline form and Imatinib Mesylate in non-crystalline form, whether on efficacy or even on solubility.

The Court also observed though without making it a ground of decision that the drug Gleevec as marketed (including in India during the EMR period) was described on its packaging as “Imatinib Mesylate Tablets” with no reference whatsoever to the beta crystalline form, which cast the claim for patent for the beta crystalline form in a somewhat poor light and suggested it was an attempt to obtain patent coverage for Imatinib Mesylate through an indirect route.

DOCTRINAL SIGNIFICANCE

This judgment is one of the most consequential decisions in the history of Indian patent law. Its significance operates on several distinct levels, each of which is strictly grounded in what the Court actually decided.

The most enduring contribution of the judgment is its authoritative interpretation of Section 3(d) of the Patents Act, 1970, as amended in 2005. The Court established that Section 3(d) constitutes an independent and distinct second tier of qualifying standards for chemical substances and pharmaceutical products, separate from the definition of “invention” in Sections 2(1)(j) and 2(1)(ja). This forecloses the argument, advanced by innovator pharmaceutical companies, that Section 3(d) is a mere explanatory or cautionary provision that adds nothing to the tests already present in the definition of “invention.” The Court made clear that even where a pharmaceutical product satisfies the novelty and inventive step requirements, it may still be denied patent if it constitutes a new form of a known substance without demonstrating enhancement of known therapeutic efficacy.

The Court’s interpretation of “efficacy” under Section 3(d) as meaning “therapeutic efficacy” in the context of pharmaceutical substances to be judged strictly and narrowly is a doctrinal holding of major practical significance. By ruling out physico-chemical properties such as flow, stability and hygroscopicity as incapable of satisfying the efficacy test and by insisting that increased bioavailability must be specifically connected to enhanced therapeutic efficacy by research data before it can be relied upon, the Court set a demanding standard for the patentability of new forms, salts, polymorphs and other derivatives of known pharmaceutical substances.

The Court’s rejection of the dichotomy between “coverage” and “disclosure” in a patent is a significant statement of the Indian position on the relationship between the claim and the enabling teaching of a specification. The Court’s express observation that it does not wish Indian patent law to develop in a direction where the scope of a patent is determined by artful claim drafting rather than the intrinsic worth of the invention is a jurisprudential marker of importance for future pharmaceutical patent disputes.

The judgment also demonstrates the Supreme Court’s methodology of purposive statutory interpretation in the domain of patent law, placing the text of the statute firmly in the context of legislative history, Parliamentary debates and the public policy objectives that informed the relevant amendments. This methodological approach which the Court itself traced to its earlier pronouncements in Utkal Contractors and Peerless General Finance is confirmed as applicable to the interpretation of the Patents Act, 1970.

It must be noted, however, that the Court expressly declined to make any categorical pronouncement on whether bioavailability falls within or outside the concept of “efficacy” for the purposes of Section 3(d), leaving that question for appropriate cases. The Court also expressly clarified that its judgment does not hold that Section 3(d) bars all incremental pharmaceutical inventions and that the deletion of Section 5 from the Patents Act remains an operative and significant change in the law.

Frequently Asked Questions:

Articles Case Laws Copyright Article Landmark Judgements on Copyrights Landmark Judgements on Patents Landmark Judgements on Trademarks Patent Article Recent Judgements on Patents Recent Judgements on Trademarks Trademark Article